-- GCI Liberty（股票代號：GLIBA，GLIBK）旗下的GCI Holdings子公司和Grain Management週三宣布，雙方已達成協議，GCI將收購阿拉斯加光纖基礎設施供應商Q Gateway Intermediate（簡稱Quintillion）。 兩家公司表示，此交易將使GCI完全擁有Quintillion，並將兩家公司的光纖網路合併，從而提升阿拉斯加地區的網路連線可靠性。 該交易的企業價值為3.1億美元，具體金額將根據慣例進行營運資本和其他調整。 GCI也將償還與諾姆至荷馬快速鐵路計畫相關的部分建設成本，最高可達5,000萬美元。如果達到特定的財務目標，GCI可能會在2028年、2029年和2031年支付額外款項。兩家公司表示，協議簽署後不久，GCI將向Quintillion提供1.6億美元的無擔保貸款。 聲明稱，該交易將在獲得監管部門批准並滿足特定條件後完成。
Price: $37.07, Change: $+0.31, Percent Change: +0.86%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.